Legend Biotech Overview
Pro stress-test →Legend Biotech is the largest standalone cell therapy company with more than 2,900 employees, specializing in CAR-T cell therapy with CARVYKTI as its lead asset, a one-time treatment for relapsed or refractory multiple myeloma developed and marketed with Johnson & Johnson collaborator. CARVYKTI has treated over 10,000 patients with global availability expanded to over 279 sites across 14 markets. The company is at an inflection point with commercial and profitability milestones approaching in 2026.
Strategic Profile
Pro stress-test →Legend Biotech expects to achieve company-wide operating profit in 2026, supported by massive expansion of its Raritan manufacturing facility. The company develops and commercializes advanced oncology treatments primarily through its Johnson & Johnson collaboration, while diversifying its pipeline into allogeneic and in vivo therapies. CARVYKTI has cemented its status as the undisputed leader in multiple myeloma CAR-T cell therapy with record-breaking performance.
Competitive Landscape
Pro stress-test →Legend is maintaining leadership in cell therapy while diversifying into allogeneic and in vivo therapies as cell therapy moves beyond traditional autologous manufacturing. CARVYKTI competes with other CAR-T therapies in multiple myeloma, while the company is also advancing pipeline candidates targeting NHL, leukemia, and solid tumors with differentiated clinical efficacy.
Industry Context
Legend Biotech operates in Biotechnology / Cell & Gene Therapy / CAR-T Cell Therapy.
Key facts
Founded: 2014 · Headquarters: Somerset, New Jersey · Employees: 2,900+ · Revenue: $524M (Q3 2025 CARVYKTI sales)